NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

CompletedPhase 4

Sponsor: Human Genome Sciences Inc., a GSK Company

Conditions: Systemic Lupus Erythematosus

Interventions: Belimumab plus Early Vaccination, Belimumab plus Late Vaccination

Countries: United States

The purpose of this study is to assess the impact of belimumab on immune response to pneumococcal vaccine in subjects with Systemic Lupus Erythematosus (SLE).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Key Inclusion Criteria:

* Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.
* Active SLE disease.
* Autoantibody-positive.
* Have antibodies with titers \>1.0 microgram (mcg)/mL to no more than 9 of the 23 serotypes present in the pneumococcal vaccine.
* Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures.

Key Exclusion Criteria:

* Pregnant or nursing.
* Have received any prior treatment with belimumab.
* Have received a live vaccine within the past 30 days.
* Have received a pneumococcal vaccination with the past 5 years.
* Have a history of severe allergic reaction to a vaccine, contrast agents (such as those used for x-rays and CT scans), or biological medicines.
* Have required management of an infection or have had infections that keep coming back within the past 60 days.
* Hepatitis B: Serologic evidence of Hepatitis B (HB) infection based on the results of testing for HB surface antigen (HBsAg) and anti-HB core antibody (anti-HBc):

  * Subjects positive for HBsAg are excluded.
  * Subjects negative for HBsAg but positive for anti-HBc, regardless of anti-HBs antibody status, are excluded.
* Hepatitis C: Positive test for Hepatitis C antibody.
* Known human immunodeficiency virus (HIV) infection.
* Have current drug or alcohol abuse or dependence.
* Have a Grade 3/4 immunoglobulin (Ig)G deficiency (IgG level \<400 milligrams \[mg\]/ deciliter \[dL\]) or IgA deficiency (IgA level \<10 mg/dL).
* Subjects who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or suicidal ideation with some intent to act in the last 2 months or who in the investigator's judgment, pose a significant suicide risk.

Locations (15)

Birmingham, Alabama, United States
Paradise Valley, Arizona, United States
Shreveport, Louisiana, United States
Baltimore, Maryland, United States
Cumberland, Maryland, United States
Hagerstown, Maryland, United States
New York, New York, United States
Toledo, Ohio, United States
Duncansville, Pennsylvania, United States
Austin, Texas, United States
Austin, Texas, United States
Houston, Texas, United States
Burlington, Vermont, United States
Seattle, Washington, United States
Spokane, Washington, United States